Small molecule inhibitors of the p53-MDM2

Related Experiment Video

Updated: Jul 3, 2026

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

Chun-Qi Hu1, Yong-Zhou Hu

  • 1College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.

Current Medicinal Chemistry
|August 5, 2008
PubMed

Insights

Researchers are developing small-molecule inhibitors to block the interaction between MDM2 (murine double minute 2) and p53. This strategy aims to reactivate the tumor-suppressor function of p53 for cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • MDM2 (murine double minute 2) protein is a key negative regulator of the p53 tumor suppressor.
  • The p53-MDM2 interaction is a critical target for cancer therapeutics due to p53's role in tumor cell eradication.
  • Understanding this interaction is crucial for developing novel anti-cancer strategies.

Purpose of the Study:

  • To review the development of MDM2 protein and the p53-MDM2 interaction.
  • To outline major classes of small-molecule inhibitors targeting the p53-MDM2 binding.
  • To discuss the medicinal chemistry and biological activities of these inhibitors.

Main Methods:

  • Literature review of MDM2 protein and p53-MDM2 interaction research.
  • Analysis of drug screening approaches and technologies for identifying inhibitors.
  • Evaluation of medicinal chemistry and biological data for small-molecule inhibitors.

Main Results:

  • Detailed history of MDM2 protein and p53-MDM2 interaction research.
  • Categorization of novel small-molecule inhibitors targeting the p53-MDM2 interaction.
  • Summary of key medicinal actions and in vitro/in vivo biological activities.

Conclusions:

  • Inhibiting the p53-MDM2 interaction is a promising therapeutic strategy in oncology.
  • Small-molecule inhibitors targeting this interaction show potential for cancer treatment.
  • Further research into these inhibitors is warranted for clinical application.

More Related Videos

Yeast As a Chassis for Developing Functional Assays to Study Human P5314:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Purification of Ubiquitinated p53 Proteins from Mammalian Cells10:55

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Published on: March 21, 2022

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...